La novità viene da uno studio fatto da molti rappresentanti del mondo scientifico,non da siti web o "grilli parlanti".Si sono chiesti se proprio il colesterolo sia il vero "colpevole" di infarti e ictus.
Lo studio Enhance dimostra come due farmaci anticolesterolo(l’ezetimibe che ne inibisce l’assorbimento intestinale e la simvastatina che ne riduce la produzione nel fegato) non siano meglio della simvastatina da sola.I due insiemo é vero che abbassano il colesterolo nel sangue,ma non producono un reale beneficio per le arterie.Viene spontanea la domanda:perchè le aziende hanno dato i risultati di questo studio in ritardo...?
Secondo un commento pubblicato sull’Herald Tribune e firmato da Gary Taubes, corrispondente della rivista Science, l’equivoco è di fondo. E cioè: si è sempre confuso il colesterolo con le proteine che lo trasportano nel sangue, le lipoproteine. Il carico with the means of transport. It has become cholesterol good or bad depending on whether conveyed by high-density lipoprotein (HDL) or low density lipoprotein (LDL). It could not therefore be cholesterol itself the true enemy (the heart attack also affects people with normal cholesterol), but abnormal lipoprotein. In fact, the two drugs together, even more by lowering your cholesterol, do not prevent the plaques. The fact remains that simvastatin and other statins prevent cardiovascular disease. E 'likely therefore that these medicines work not because they lower cholesterol, but because they act through other mechanisms, such as reducing inflammation.
Despite these doubts, however, the FDA, the American authority to control drugs, it continues to medicines for the prevention of heart disease only on the grounds that reduce LDL and health authorities undertake prevention campaigns focusing on cholesterol. Forgetting at times that the medications have side effects that are worth addressing if the benefits are real. And many wonder what the role of the pharmaceutical industry. Industry that, in the case of the Enhance study, revealed two years later the negative results, leaving millions of patients who continued therapy. The fact is that the anti-cholesterol market is simply huge. An example: in 2005 the turnover of atorvastatin was more than 12 billion dollars.
industries have a common interest in promoting the cholesterol hypothesis, to enlarge the proportion of consumers of anti-cholesterol drugs (they did so by reducing more and more normal levels in the blood in order to create more "sick" as he has reported the British Medical Journal) and play good cholesterol hypothesis (to rise) and bad (to reduce) to propose new molecules since they are running out of those old patents. Too bad that a drug with new mechanism of action, the torcetrapib , instead of preventing heart attacks causes and stroke them (the study was discontinued a year ago ). Further evidence that the cholesterol is no longer fashionable?
Source Courier
Some non-conventional medical statements:
" We would be happy if we could have even a single verifiable study that demonstrated that human lives can be saved by lowering cholesterol. Instead, we have no trouble finding ten studies showing that a decrease in lipid corresponds to a higher mortality . Cardiologist Harald Klepzig lnstitute German cardiology Frankfurt
Paul Rosch, president American Institute of Stress and professor of medicine at New York Medical College, said: "The brainwashing that has suffered the public has worked so well that many people believe to be healthy or to live longer if you have low cholesterol. Instead, there is nothing further from the truth. "
The presence of so-called statins prevent the body from forming in it called mevalonic acid, which is necessary for the synthesis of cholesterol. In this case, the body's cells must acquire cholesterol from food, so the rate of cholesterol in the blood decreases. This feature makes the statin esse siano un prodotto d'importanza capitale per l'industria farmaceutica. Le persone che possono averne bisogno sono moltissime: sono cioè tutti quegli individui il cui tasso di colesterolo è già stato definito troppo alto e che quindi hanno bisogno di cure. Si tratta di persone che, a parte il colesterolo alto, stanno bene di salute e quindi possono vivere tanto a lungo da dover assumere statine tutti i giorni per decenni. In effetti le sostanze che impediscono la formazione del colesterolo si sono dimostrate vere e proprie macchine per far soldi sul mercato dei prodotti farmaceutici, soprattutto perché sono state brevettate e si possono acquistare soltanto a caro prezzo (all'incirca da uno a due euro per ogni dose giornaliera). La Pfizer con la sua statin called Lipitor expects to reach an annual turnover of ten billion dollars: Lipitor is already the best-selling pharmaceutical product of all time. The competing product, the company's Zocor Merck & Co., arrived at least a staggering 7.5 billion dollars. In the United States 5.4% of the adult population in the world take statins, and there are 44 million consumers.
Obviously this is not to say that you can eat the most disgusting things in the world in industrial quantities ....... but at least we are aware of a possible hidden truth or falsehood revealed ....!Pages Medicine Diseases Drugs
0 comments:
Post a Comment